Vergelijking

Nafarelin vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

geen gegevens

396091-73-9

Molecuulmassa

geen gegevens

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Nafarelin

Nafarelin is a potent GnRH agonist: after an initial stimulation ('flare'), continuous receptor occupancy leads to downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Nafarelin	Pasireotid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Nafarelin

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Nafarelin and Pasireotid?: Nafarelin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Nafarelin or Pasireotid?: The highest available evidence level is "Humane RCT" for Nafarelin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Nafarelin and Pasireotid in Germany and the United States?: Duitsland: Nafarelin — Op recept, Pasireotid — Op recept. Verenigde Staten: Nafarelin — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Nafarelin

Pasireotid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Nafarelin and Pasireotid?

Nafarelin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Nafarelin or Pasireotid?

The highest available evidence level is "Humane RCT" for Nafarelin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Nafarelin and Pasireotid in Germany and the United States?

Duitsland: Nafarelin — Op recept, Pasireotid — Op recept. Verenigde Staten: Nafarelin — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.